B-cell Lymphomas malady

MalaCards: B-cell Lymphomas, also known as lymphoma, b-cell, is related to diffuse large b-cell lymphoma and leukemia. An important gene associated with B-cell Lymphomas is BCL6 (B-cell CLL/lymphoma 6), and among its related pathways are STAT3 Pathway and Tec Kinases Signaling. The drugs mitoxantrone and rituximab and the compounds atp and oxygen have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and lung, and related mouse phenotypes are cellular and mortality/aging.

b-cell lymphomas 30 43 lymphoma, b-cell 30 33

lymphoma b-cell 32 lymphoma 43

Disease types for b-cell lymphomas family:

t-cell lymphoma 1a

Diseases related to b-cell lymphomas by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1000)

id	Related Disease	Score	Top Affiliating Genes
1	diffuse large b-cell lymphoma	103.8	PIK3CA, PIK3CG, PIM1, RFX1, NCAM1, PDE4A
2	leukemia	82.2	ZNF673, ZNF296, ZNF521, PIK3CA, PIR, PIK3CG
3	carcinoma	75.4	ZNF673, PIGR, PIK3CA, PIR, PIM3, PIK3CG
4	prostatitis	66.2	ZNF673, PIK3CA, PIK3CG, PIM1, NCAM1, NCOR1
5	lymphocytic leukemia	63.9	PIK3CA, PIK3CG, NCAM1, PDE4A, PDE4B, RECK
6	adenocarcinoma	60.4	PIGR, PIK3CA, PIM3, PIK3CG, PIM1, LRMP
7	myeloma	59.9	PIK3CA, PIK3CG, NCAM1, NCOR2, PDE4A, RECK
8	melanoma	58.6	PIK3CA, PIR, PIK3CG, PIM1, NCAM1, PDE4A
9	pancreatitis	57.9	PIK3CA, PIM3, PIK3CG, PIM1, NCAM1, PDE4A
10	neuronitis	57.4	PIK3CA, PIK3CG, PIM1, RFX1, NCAM1, NCOR1
11	hepatocellular carcinoma	55.8	PIGR, PIK3CA, PIM3, PIK3CG, NCAM1, RECK
12	arthritis	55.8	PIK3CG, PDE4A, RECK, REL, RELA, CNR2
13	myeloid leukemia	55.0	ZNF673, ZNF296, PIK3CA, PIR, PIK3CG, PIM1
14	gastric cancer	54.7	PIK3CA, PIK3CG, PIM1, RECK, RELA, KIT
15	thyroiditis	52.4	PIK3CA, PIK3CG, NCAM1, NCOR1, NCOR2, PDE4A
16	sarcoma	52.3	PIK3CA, PIK3CG, NCAM1, PDE4A, RECK, RELA
17	lymphoblastic leukemia	52.2	ZNF521, PIK3CA, PIK3CG, SH2D4B, NCAM1, RECK
18	cervicitis	51.3	PIK3CA, PIK3CG, PDE4A, RECK, RELA, KIT
19	colon cancer	50.8	PIK3CA, PIM3, PIK3CG, NCAM1, NCOR2, PDE4A
20	lupus erythematosus	50.4	PIK3CG, RECK, REL, KIR3DL1, NBN, SELE
21	hypoxia	50.0	PIK3CA, PIK3CG, PIM1, PDE4A, RECK, RELA
22	nasopharyngitis	48.8	PIGR, PIK3CA, PIK3CG, RECK, RELA, KIT
23	acute myeloid leukemia	48.5	ZNF673, ZNF296, PIK3CA, PIR, PIK3CG, PIM1
24	neuroblastoma	48.2	PIK3CA, PIK3CG, RFX1, NCAM1, NCOR2, PDE4A
25	anemia	47.3	PIM1, RFX1, NCAM1, NCOR1, RELA, KIT
26	acute leukemia	46.5	PIK3CA, NCAM1, NCOR1, NCOR2, KIT, RB1
27	adenoma	46.3	PIK3CA, PIM3, LRMP, NCAM1, NCOR1, NCOR2
28	non-hodgkin lymphoma	45.4	ZNF673, NCOR2, CNR2, RBL1, NBN, SELL
29	hodgkin's lymphoma	45.4	PIK3CG, REL, SERPINB9, BRCA1, BRCA2, BMI1
30	astrocytoma	44.3	PIK3CA, PIK3CG, NCAM1, RECK, RELA, CNR2
31	burkitt's lymphoma	44.0	MYC, MYCN, MYB, MYBL1, BMI1, RAG1
32	t-cell leukemia	43.4	PIK3CG, REL, RELA, LMO2, VAV1, MYC
33	chronic lymphocytic leukemia	43.4	PDE4A, REL, SELL, BRCA2, MYB, BIRC3
34	breast carcinoma	43.3	PIK3CA, PIK3CG, NCOR1, RECK, CNR2, KIT
35	fibrosis	43.2	PIK3CA, PIK3CG, PDE4A, RECK, RELA, CNR2
36	asthma	43.2	PIK3CA, PIK3CG, PDE4A, PDE4B, RECK, KIT
37	central nervous system lymphoma	42.9	PIM1, RB1, VEGFA, LPP, MYC, BIRC5
38	retinoblastoma	42.9	PIK3CA, PIK3CG, NCAM1, RECK, KIT, RB1
39	cerebritis	42.8	PIK3CG, NCAM1, PDE4A, RELA, SELE, SERPINB2
40	pneumonia	42.7	PIGR, PDE4A, RELA, BTK, SELE, SELL
41	anaplastic large cell lymphoma	42.7	PIK3CA, RECK, KIT, RB1, SERPINB9, MYC
42	follicular lymphoma	42.4	REL, MYC, MYB, BMI1, BIRC3, PAX5
43	mediastinitis	42.3	PIK3CG, REL, KIT, SELE, VEGFC, MYC
44	leukemia/lymphoma	42.3	PIK3CA, PIK3CG, REL, RB1, NBN, VEGFA
45	marginal zone b-cell lymphoma	42.1	PIM1, RB1, BIRC3, PAX5, BCL10, BCL3
46	colon carcinoma	41.6	PIGR, PIK3CA, PIK3CG, NCAM1, KIT, BTK
47	cutaneous t cell lymphoma	41.2	SELE, SELL, MYB, BIRC5, BAX, CDKN2B
48	acute lymphoblastic leukemia	40.9	RECK, KIT, KIR3DL1, BTK, RB1, NBN
49	immunodeficiency	40.5	KIR3DL1, BTK, SELL, PARP1, BCR, LGALS1
50	lung carcinoma	40.4	PIGR, PIK3CA, PIK3CG, NCAM1, PDE4A, RELA

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 asparaginase, cytarabine, cytarabine liposome, doxorubicin hydrochloride, ibritumomab tiuxetan, irinotecan, irinotecan hydrochloride, mitoxantrone, mitoxantrone hydrochloride, rituximab, thiotepa

MalaCards organs/tissues related to b-cell lymphomas:

²²

MGI Mouse Phenotypes related to b-cell lymphomas:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular phenotype	MP:0005384	32.4	PIK3CA, PIM3, PIK3CG, PIM1, NCAM1, NCOR1
2	mortality/aging	MP:0010768	28.5	PIK3CA, RFX1, NCAM1, NCOR1, NCOR2, PDCD2
3	hematopoietic system phenotype	MP:0005397	27.3	PIGR, PIM3, PIM1, KIT, VSIG4, BTK
4	homeostasis/metabolism phenotype	MP:0005376	26.7	PIGR, PIK3CA, PIK3CG, NCOR1, NCOR2, REL
5	growth/size phenotype	MP:0005378	24.9	ZNF521, PIK3CA, PIR, PIM3, PIK3CG, PIM1
6	immune system phenotype	MP:0005387	24.2	PIGR, PIM3, NCOR1, PDE4A, PDE4B, REL
7	tumorigenesis	MP:0002006	20.3	PIK3CA, KIT, BTK, RB1, RBL1, NBN
8	integument phenotype	MP:0010771	20.3	PIK3CG, NCOR1, RECK, REL, RELA, CNR2
9	cardiovascular system phenotype	MP:0005385	19.5	PIK3CA, PIK3CG, NCOR2, PDE4A, PDE4B, RECK
10	nervous system phenotype	MP:0003631	18.8	NCOR1, PDE4A, PDE4B, RECK, REL, RELA
11	normal phenotype	MP:0002873	18.7	PIM3, RELA, RBL1, SELE, BRCA1, BRCA2
12	behavior/neurological phenotype	MP:0005386	18.3	PIK3CA, NCAM1, NCOR1, NCOR2, KIT, RB1
13	digestive/alimentary phenotype	MP:0005381	17.7	PIGR, NCOR2, REL, KIT, BTK, RB1
14	reproductive system phenotype	MP:0005389	16.0	PIGR, PIK3CA, RBL1, NBN, BRCA1, BRCA2
15	embryogenesis phenotype	MP:0005380	15.9	PIK3CA, PIR, NCOR1, PDCD2, RECK, REL
16	renal/urinary system phenotype	MP:0005367	15.5	KIT, BRCA1, LMNA, LMO2, MYCN, RAG1
17	vision/eye phenotype	MP:0005391	15.5	PIK3CA, NCAM1, RELA, KIT, RB1, RBL1
18	muscle phenotype	MP:0005369	15.3	PIK3CA, PIK3CG, NCOR1, RELA, KIT, RB1
19	no phenotypic analysis	MP:0003012	15.1	RB1, RBL1, VEGFA, VCAM1, MYC, PARP1
20	skeleton phenotype	MP:0005390	15.1	ZNF521, PIK3CG, RECK, REL, RELA, KIT
21	respiratory system phenotype	MP:0005388	14.3	REL, SELL, BRCA1, MYCN, RAG1, BCL6
22	liver/biliary system phenotype	MP:0005370	14.2	NCOR1, NCOR2, RECK, REL, KIT, RBL1
23	endocrine/exocrine gland phenotype	MP:0005379	13.9	RBL1, NBN, SELL, BRCA1, BRCA2, BRD2
24	limbs/digits/tail phenotype	MP:0005371	12.9	RECK, RELA, KIT, BTK, RB1, RBL1
25	pigmentation phenotype	MP:0001186	12.9	KIT, RB1, BRCA1, LMNA, MYC, RAG1
26	craniofacial phenotype	MP:0005382	12.5	ZNF521, NCOR2, KIT, RBL1, NBN, MYCN
27	adipose tissue phenotype	MP:0005375	12.1	PIK3CA, NCOR1, NCOR2, RB1, RBL1, BRCA1
28	hearing/vestibular/ear phenotype	MP:0005377	11.9	KIT, RB1, LMNA, MYC, RAG1, RARB
29	other phenotype	MP:0005395	10.9	RECK, RARB, KDR, LEPR, JAK2, CDKN2A

Articles related to b-cell lymphomas:

(show top 50)    (show all 1044)

id	Title	Authors	Year	Affiliating Genes
1	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. (21646687)	Forshell L.P.... Nilsson J.	2011	MYC, PIM3
2	H2AFX polymorphisms are associated with decreased ris k of diffuse large B cell lymphoma in Koreans. (21631283)	Jin X.M.... Choi C.	2011	H2AFX
3	Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. (20938662)	Ninomiya S.... Moriwaki H.	2011	IDO1
4	Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature. (20507739)	Zhang H.Y.... Wang J.X.	2010	IRF4
5	Anticancer therapy SMRT-ens up: targeting the BCL6-SM RT interaction in B cell lymphoma. (20385356)	Compton L.A.... Hiebert S.W.	2010	BCL6
6	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. (20956547)	Miletic A.V.... Rickert R.C.	2010	PTEN
7	Dose-intensified treatment of Burkitt lymphoma and B- cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a compar ison of two adapted BFM protocols. (20201088)	Tauro S.... Holte H.	2010	CSF3
8	Somatic mutations altering EZH2 (Tyr641) in follicula r and diffuse large B-cell lymphomas of germinal-center origin. (20081860)	Morin R.D.... Marra M.A.	2010	EZH2
9	T-cell leukemia 1 expression in nodal Epstein-Barr vi rus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymph oma. (20382409)	Gualco G.... Bacchi C.E.	2010	TCL1A
10	B-cell lymphomas with concurrent IGH-BCL2 and MYC rea rrangements are aggressive neoplasms with clinical and pathologic features dist inct from Burkitt lymphoma and diffuse large B-cell lymphoma. (20118770)	Snuderl M.... Sohani A.R.	2010	MYC, BCL2
11	Burkitt lymphoma versus diffuse large B-cell lymphoma : a practical approach. (19670467)	Bellan C.... Lorenzo L.	2009	MYC
12	Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. (19141121)	Nyman H.... LeppAo S.	2009	BCL2, FOXP1
13	BCL6 modulates tonic BCR signaling in diffuse large B -cell lymphomas by repressing the SYK phosphatase, PTPROt. (19855081)	Juszczynski P.... Shipp M.A.	2009	BCR, SYK, BCL6
14	Differential regulation of the antiapoptotic action o f B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra long (Bcl-xL) by c-Jun N- terminal protein kinase (JNK) 1-involved pathway in neuroglioma cells. (18758060)	Jeong H.S.... Cho S.G.	2008	MAPK8
15	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. (18633131)	Habermann T.M.... Cerhan J.R.	2008	ICAM1, JAK3, TNF
16	TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. (17886247)	Honma K.... Seto M.	2008	TNFAIP3
17	A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. (18343791)	Ehinger M.... Cavallin-Stahl E.	2008	CCND1
18	Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. (18728972)	Fridberg M.... Wingren A.G.	2008	PTPN11, PTEN, PTPN7
19	Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH/BCL2 and the t(14;18)(q32;q21) IGH/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma? (17519619)	Palmedo G.... Kutzner H.	2007	MALT1
20	Neural cell adhesion molecule (CD56)-positive B-cell lymphoma. (17635242)	Isobe Y.... Oshimi K.	2007	NCAM1
21	Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. (17325859)	Lacrima K.... Bertoni F.	2007	CCNH, CCNT1
22	Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. (17492759)	Kim W.S.... Ko Y.H.	2007	MALT1
23	Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. (16871282)	Weniger M.A.... Barth T.F.	2006	BCL11A
24	Expression of Ki-67, transforming growth factor beta1, and B-cell lymphoma-leukemia-2 in liver tissue of patients with chronic liver diseases. (16677156)	Piekarska A.... Kubiak R.	2006	TGFB1
25	Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. (16287070)	Melzner I.... Moller P.	2006	JAK2, SOCS1
26	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. (15920553)	Berglund M.... Enblad G.	2005	IRF4
27	Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements. (16049306)	George T.I.... Arber D.A.	2005	PAX5
28	Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. (15943789)	Watanuki-Miyauchi R.... Takami T.	2005	BIRC5
29	T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases. (15894921)	Wang J.... Weiss L.M.	2005	BCL2
30	NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. (15870177)	Feuerhake F.... Shipp M.A.	2005	NFKB1, REL
31	Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. (14592832)	Montesinos-Rongen M.... Deckert M.	2004	MYC, PIM1, PAX5
32	Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. (14691303)	Koyama M.... Seino Y.	2003	PTPN6
33	Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. (12574966)	Kroschinsky F.... Ehninger G.	2003	DNTT
34	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. (12933571)	Savage K.J.... Shipp M.A.	2003	JAK2, STAT1, TRAF1
35	Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. (12827616)	Ree H.J.... Mori S.	2003	BCL6
36	Immunohistochemical analysis of B-cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B-cell lymphomas. (12940773)	Zettl A.... Ott G.	2003	TP53, MS4A1
37	Pathobiology of primary mediastinal B-cell lymphoma. (15202521)	Pileri S.A.... Cavalli F.	2003	SPI1, SLC22A2
38	Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. (11857494)	Dukers D.F.... Meijer C.J.	2002	CASP3, PARP1
39	Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. (11298531)	Child F.J.... Whittaker S.J.	2001	BCL2
40	Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. (11567225)	Ree H.J.... Charney D.	2001	BCL6
41	Comparison of apoptosis and apoptosis-related gene products between extranodal oral B-cell lymphoma and maxillofacial nodal B-cell lymphoma. (11271628)	Yin H.... Takagi M.	2001	BCL2
42	MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. (10753849)	Dyomin V.G.... Chaganti R.S.	2000	MUC1
43	Primary, localized vulvar B-cell lymphoma expressing CD44 variant 6 but not cadherins. A case report. (11077639)	Iczkowski K.A.... Rosenblum N.G.	2000	CD44
44	The IgA/IgM receptor expressed on a murine B cell lymphoma is poly-Ig receptor. (10946281)	Phillips-Quagliata J.M.... Corthesy B.	2000	CD40LG, PIGR
45	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myc transcriptional regulation. (10910917)	Arsura M.... Sonenshein G.E.	2000	MYC, MYBL1
46	Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. (10086736)	Moller M.B.... Pedersen N.T.	1999	MDM2, CDKN2A
47	T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. (9846961)	Felgar R.E.... Macon W.R.	1998	BCL2, GZMB, MKI67
48	CD5-expressing B-cell lymphomas/leukemias: relatively high frequency of CD5+ B-cell lymphomas with an overall poor prognosis in Nagasaki Japan. (8724541)	Kamihira S.... Tomonaga M.	1996	CD5
49	Detection of BCL2 rearrangement in archival cytological smears of B-cell lymphomas. (7892160)	Shivnarain D.... Zakowski M.F.	1994	BCL2
50	Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. (8062825)	Lovec H.... MAPrAPy T.	1994	MYC, CCND1, MYCN

Genes related to b-cell lymphomas according to GeneCards:

(show top 50)    (show all 611)

id	Symbol	Description	Score	GeneCards Section Context
1	BCL6	B-cell CLL/lymphoma 6	11.1	Publications, Aliases & Descriptions, Proteins, Orthologs
2	PIM1	pim-1 oncogene	11.1	Publications, Summaries
3	BCL3	B-cell CLL/lymphoma 3	11.1	Publications, Aliases & Descriptions
4	PASD1	PAS domain containing 1	11.1	Publications, Expressions, Summaries
5	BCL10	B-cell CLL/lymphoma 10	11.1	Publications, Aliases & Descriptions, Proteins
6	CCND1	cyclin D1	11.1	Publications, Aliases & Descriptions
7	BCL11B	B-cell CLL/lymphoma 11B (zinc finger protein)	11.1	Aliases & Descriptions, Proteins, Orthologs
8	SNHG5	small nucleolar RNA host gene 5 (non-protein coding)	11.1	Publications, Summaries
9	BCL11A	B-cell CLL/lymphoma 11A (zinc finger protein)	11.1	Publications, Aliases & Descriptions, Proteins, Orthologs
10	BCL9L	B-cell CLL/lymphoma 9-like	11.1	Aliases & Descriptions
11	BCL9	B-cell CLL/lymphoma 9	11.1	Aliases & Descriptions
12	TP53	tumor protein p53	11.0	Publications
13	IRF4	interferon regulatory factor 4	11.0	Publications
14	MALT1	mucosa associated lymphoid tissue lymphoma translocation gene 1	11.0	Publications, Functions
15	BIRC3	baculoviral IAP repeat containing 3	11.0	Publications
16	PAX5	paired box 5	11.0	Publications
17	RHOH	ras homolog family member H	11.0	Publications
18	TNFAIP3	tumor necrosis factor, alpha-induced protein 3	11.0	Publications
19	ATM	ataxia telangiectasia mutated	11.0	Publications
20	CD40LG	CD40 ligand	11.0	Publications
21	CD79A	CD79a molecule, immunoglobulin-associated alpha	11.0	Publications
22	CDKN2A	cyclin-dependent kinase inhibitor 2A	11.0	Publications
23	FAS	Fas (TNF receptor superfamily, member 6)	11.0	Publications
24	IL10	interleukin 10	11.0	Publications
25	RB1	retinoblastoma 1	11.0	Publications
26	TLR4	toll-like receptor 4	11.0	Publications
27	PIR	pirin (iron-binding nuclear protein)	11.0	Summaries
28	BCL2L13	BCL2-like 13 (apoptosis facilitator)	11.0	Summaries
29	MIR127	microRNA 127	11.0	Publications
30	MIR28	microRNA 28	11.0	Publications
31	PRG1	p53-responsive gene 1	11.0	Publications
32	BECN1P1	beclin 1, autophagy related, pseudogene 1	11.0	Publications
33	MIR125B1	microRNA 125b-1	11.0	Publications
34	IGHV@	immunoglobulin heavy variable cluster	11.0	Publications
35	MIR155HG	MIR155 host gene (non-protein coding)	11.0	Publications
36	MIR223	microRNA 223	11.0	Publications
37	TCL1A	T-cell leukemia/lymphoma 1A	11.0	Publications
38	MIR17	microRNA 17	11.0	Publications
39	MIRLET7A1	microRNA let-7a-1	11.0	Publications
40	MS4A1	membrane-spanning 4-domains, subfamily A, member 1	11.0	Publications
41	MSC	musculin	11.0	Publications
42	PARP9	poly (ADP-ribose) polymerase family, member 9	11.0	Expressions, Publications, Functions
43	CD5	CD5 molecule	11.0	Publications
44	IGKC	immunoglobulin kappa constant	11.0	Publications
45	MIR155	microRNA 155	11.0	Publications
46	PRDM1	PR domain containing 1, with ZNF domain	11.0	Publications
47	DTX3L	deltex 3-like (Drosophila)	11.0	Publications
48	FCRLA	Fc receptor-like A	11.0	Expressions
49	IGH@	immunoglobulin heavy locus	11.0	Publications
50	IGHM	immunoglobulin heavy constant mu	11.0	Publications

Pathways related to b-cell lymphomas according to GeneDecks:

(show top 50)    (show all 360)

id	Pathway	Score	Top Affiliating Genes
1	STAT3 Pathway36	15.8	PIM1, BTK, MYC, BCL2, BAX, XCR1
2	Tec Kinases Signaling36	15.7	BTK, VEGFC, VAV1, BCL2, BAX, XCR1
3	Akt Signaling36	15.2	PIK3CG, KIT, BTK, VEGFC, CHUK, XCR1
4	Measles20	14.6	PIK3CA, PIK3CG, RELA, CHUK, JAK2, CDK2
5	Immune System38	14.5	NCAM1, REL, KIR3DL1, VCAM1, BLK, BLNK
6	Apoptosis20	14.2	PIK3CA, PIK3CG, RELA, BIRC3, BCL2, BCL2L1
7	Apoptosis and Autophagy3	14.2	PIR, PIM3, PIM1, LMNA, MYC, MYCN
8	Rho Family GTPases36	14.0	KIT, BTK, VEGFC, KDR, BCL2, BAX
9	TGF-Beta Pathway36	13.8	BTK, VEGFC, KDR, BCL2, BAX, JUN
10	Toxoplasmosis20	13.7	PIK3CA, PIK3CG, RELA, BIRC3, BCL2, BCL2L1
11	SOCS Pathway36	13.6	BTK, VEGFC, BCL2, BAX, JAK2, CD80
12	Tuberculosis20	13.4	RFXAP, RELA, BCL10, BCL2, CIITA, BAD
13	NF-KappaB Family Pathway36	13.4	REL, RELA, VEGFC, VAV1, BLK, KDR
14	NF-kappaB Signaling3	13.4	PIR, REL, RELA, BCL10, CHUK, IRF1
15	Small cell lung cancer20	13.4	PIK3CA, PIK3CG, RELA, RB1, MYC, RARB
16	Signal transduction_AKT signaling41	13.3	PIK3CA, REL, RELA, MYC, BCL2L1, BCL2L11
17	Chemokine signaling pathway20	13.2	PIK3CA, PIK3CG, RELA, VAV1, CHUK, XCR1
18	PGC1Alpha Pathway36	13.1	BTK, BCL2, BAX, CD80, IL10RA, IL12A
19	Development IGF-RI signaling10	13.0	PIK3CA, REL, RELA, MYC, BCL2L1, CHUK
20	Glucocorticoid Receptor Signaling36	12.9	NCOR1, NCOR2, BTK, BCL2, BAX, JUN
21	Mitochondrial Apoptosis36	12.9	KIT, VEGFC, KDR, BCL2, BCL2L1, BCL2L11
22	NFAT Signaling and Lymphocyte Interactions36	12.9	BTK, BCL2, BAX, CD80, FCER2, IL12A
23	NFAT in Immune Response36	12.8	KIT, BTK, VEGFC, BLNK, KDR, CHUK
24	Immune response_IL-4 signaling pathway41	12.8	PIK3CA, REL, RELA, CHUK, MTOR, INPP5D
25	Immune response IL-4 signaling pathway10	12.7	REL, RELA, CHUK, MTOR, INPP5D, GRB2
26	NF-KappaB (p50-p65) Pathway36	12.6	RELA, VEGFC, KDR, CHUK, FLT1, FLT4
27	RAR-Gamma-RXR-Alpha Degradation36	12.5	BTK, CD80, IL12A, IL15, IL16, IL2
28	CD28 Signaling in T-Helper Cell36	12.3	VAV1, BCL10, ZAP70, CD86, MALT1, CARD11
29	Chagas disease (American trypanosomiasis)20	12.2	PIK3CA, PIK3CG, RELA, CHUK, CFLAR, JUN
30	Breast Cancer Regulation by Stathmin136	12.2	MST1R, FIGF, GRB2, IL9, MAPK11, CCNE1
31	14-3-3 Induced Apoptosis36	12.2	BCL2, CHUK, BAD, JUN, IL1A, IL1B
32	Immune response_Fc epsilon RI pathway41	12.2	PIK3CA, REL, RELA, BTK, VAV1, BLNK
33	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway10	12.1	REL, RELA, BCL2, BCL2L1, CHUK, CD40LG
34	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway10	12.1	REL, RELA, BIRC3, BIRC5, CHUK, XIAP
35	Hepatitis C20	12.0	PIK3CA, PIK3CG, RELA, CHUK, BAD, CDKN1A
36	Apoptosis and survival APRIL and BAFF signaling10	11.9	RELA, BCL2, BCL2L1, CHUK, FCER2, IL10
37	Immune response Fc epsilon RI pathway10	11.9	PIK3CA, REL, RELA, BTK, VAV1, BLNK
38	Non-small cell lung cancer20	11.8	PIK3CA, PIK3CG, RB1, BAD, CDKN2A, CDK4
39	Cytokine production by Th17 cells in CF (Mouse model)41	11.8	REL, RELA, CHUK, JAK2, CD14, FOXP3
40	Immune response_MIF-JAB1 signaling41	11.6	NCOR1, RELA, JUN, CDK2, CDKN1B, CDK4
41	Immune response IL-2 activation and signaling pathway10	11.6	PIK3CA, REL, MYC, CHUK, LCK, JUN
42	Development Prolactin receptor signaling10	11.4	PIK3CA, RELA, VAV1, MYC, BCL2, BCL2L1
43	Renin-Angiotensin Pathway36	11.3	KIT, VEGFC, VCAM1, KDR, CHUK, JUN
44	Pertussis20	11.2	RELA, JUN, CD14, ITGB1, ITGB2, IRF1
45	Signal transduction AKT signaling10	11.2	REL, NFKB2
46	Immune response_IFN gamma signaling pathway41	11.1	PIK3CA, BRCA1, MYC, JAK2, CDKN1A, IRF1
47	Amoebiasis20	11.0	PIK3CA, RELA, SERPINB9, SERPINB2, MUC2, CD14
48	Immune response IFN gamma signaling pathway10	10.9	JAK2, MAPK11, IFNG, IFNGR2, AKT1, SRC
49	Development_EGFR signaling pathway41	10.6	PIK3CA, REL, MYC, CHUK, JUN, GRB2
50	TGF-beta Signaling Pathways37	10.2	PIK3CG, NCOR1, NCOR2, REL, RELA, MYC

Compounds related to b-cell lymphomas according to GeneDecks:

(show top 50)    (show all 420)

id	Compound	Score	Top Affiliating Genes
1	atp32	18.7	PIK3CA, PIM1, NCAM1, PDE4A, RECK, KIT
2	oxygen32 18	19.1	RB1, BRCA1, MYB, BIRC3, BIRC5, PARP1
3	superoxide32 18	17.0	PIK3CA, PDE4A, RB1, SELL, SERPINB2, VCAM1
4	rantes32	15.9	REL, SELE, SELL, VCAM1, CIITA, CHUK
5	lactate32	15.3	PIK3CA, NCAM1, RECK, KIT, SELE, SELL
6	cysteine32	14.5	RECK, REL, BTK, BRCA1, MYB, RAG1
7	leucine32	14.4	PIGR, PIK3CA, RECK, KIT, KIR3DL1, RB1
8	ascorbic acid32 18	15.2	PIK3CG, SERPINB2, CHUK, XRCC1, JAK2, CD40LG
9	5-aza-2deoxycytidine32	14.0	KIR3DL1, BRCA1, BNIP3, MYC, RARB, CIITA
10	cytarabine32 34 9 9	16.8	KIT, RB1, MYC, BCL2, BCL2L1, BCR
11	adp32 18	14.6	PIK3CA, PIM3, PIK3CG, PIM1, RECK, KIT
12	flavopiridol32 9 9	15.5	PIK3CG, KIT, RB1, RBL1, VEGFA, BIRC5
13	p00232	13.2	KIT, RB1, BRCA1, BRCA2, BIRC5, MVP
14	estradiol32 9 18 9	16.2	NCOR1, NCOR2, RB1, BRCA1, BRCA2, VEGFC
15	tgf beta132	13.1	RBL1, VCAM1, KDR, CDKN1A, CDK2, CDKN2B
16	dutp32	13.1	BIRC5, PARP1, BCL2, BCL2L1, LGALS3, BAK1
17	bortezomib32 9 9	15.0	BRCA1, VEGFA, MYC, BIK, BIRC5, PARP1
18	thalidomide32 42 9 9	16.0	PDE4A, SELL, VEGFA, BIRC3, BIRC5, KDR
19	simvastatin32 34 42 9 18 9	18.0	SELE, SELL, VEGFA, VCAM1, PAX5, KDR
20	curcumin32	12.9	PIK3CG, VEGFA, VCAM1, MYC, BIRC3, BIRC5
21	lovastatin32 42 9 9	15.9	RB1, RBL1, LMNA, XIAP, CDKN1A, CDK2
22	matrigel32	12.8	PIK3CA, PIK3CG, NCAM1, RB1, SELE, SERPINB2
23	bleomycin32 9 9	14.8	BRCA1, BRCA2, MVP, XRCC1, ATM, CDKN3
24	troglitazone32 42 9 9	15.8	PIK3CG, RB1, SELE, VCAM1, BIRC5, BCL2
25	ceramide32	12.7	PIK3CA, RB1, BNIP3, BCL2L1, BCL2L11, LGALS1
26	prednisolone32 9 9	14.7	SELL, VCAM1, MYC, MVP, MPO, CD79A
27	biotin32 9 18 9	15.4	RB1, SELL, MUC1, B2M, MSH2, CD79A
28	nocodazole32 42 9 9	15.4	PIGR, BRCA1, BIRC5, CHEK2, BAG1, CD79A
29	dihydrofolate32	12.3	RB1, RBL1, BRD2, MTHFR, MTR, CDK2
30	geldanamycin32 9 9	14.3	PIK3CG, PIM1, VEGFA, BIRC5, PARP1, KDR
31	carboplatin32 34 9 9	15.3	RB1, BRCA1, VEGFA, PARP1, KDR, BCL2
32	calcitriol32 42 9 18 9	16.2	RB1, MYC, RARB, PAX5, BAK1, XIAP
33	ifn-alpha32	12.2	CDK2, CDKN2A, IRF1, IL10, IL13, IL2
34	polyacrylamide32	12.2	RECK, RB1, BRCA1, BRCA2, LGALS1, LGALS3
35	agar32	12.2	PIK3CA, RB1, BRCA1, MYCN, RARB, BIRC5
36	17-(allylamino)-17-demethoxygeldanamycin32	12.1	KIT, BIRC5, CHEK2, CDKN1A, CDK4, CDH1
37	phosphatidylserine32 9 9	14.0	RECK, SELE, PARP1, BCL2, BCL2L11, LGALS1
38	nadph32 18	13.0	PIK3CA, KDSR, XRCC1, XPC, MGMT, AKT1
39	sodium nitroprusside32	11.9	PDE4A, MYB, CD40, MME, IL12B, IL13
40	sp 60012532 42	12.9	PIK3CG, VCAM1, BIK, BIRC3, CDKN1A, CD40
41	phenylalanine32	11.7	BTK, VAV1, BCR, CIITA, ZAP70, LCK
42	il-1232	11.6	CD86, CD40LG, IL10, IL12B, IL13, IL15
43	atorvastatin32 34 9 18 9	15.6	SELE, SELL, VEGFA, VCAM1, CD59, CD40LG
44	vinblastine32 9 9	13.5	BIRC5, KDR, BCL2, BCL2L1, MVP, BAX
45	methylmethanesulfonate32	11.4	NBN, BRCA1, BRCA2, PARP1, XRCC1, JUN
46	triptolide32	11.3	VEGFA, BIRC3, PARP1, BCL2, BAX, JUN
47	sodium arsenite32	11.1	MYC, LBR, CFLAR, JUN, IL1A, IL2RA
48	rottlerin32 42	12.0	PIK3CG, VCAM1, PARP1, XIAP, JUN, CD40LG
49	rosiglitazone32 9 18 9	13.9	PIK3CA, PIK3CG, NCOR1, SELE, VCAM1, LMNA
50	ns 39832 42	11.3	PIK3CG, PARP1, CDKN1B, IL1A, IL1B, IL8

Cellular components related to b-cell lymphomas according to GeneDecks:

(show all 11)

id	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:005634	26.5	ZNF296, ZNF521, PIR, PIM1, RFX1, RFXAP
2	cytoplasm	GO:005737	25.0	PIR, PIM3, PIK3CG, PIM1, PDCD2, RELA
3	cytosol	GO:005829	20.2	PIK3CA, PIK3CG, PDE4A, PDE4B, REL, RELA
4	plasma membrane	GO:005886	19.2	PIK3CG, PIM1, NCAM1, RECK, CNR2, KIT
5	nucleoplasm	GO:005654	16.2	NCOR1, NCOR2, REL, RELA, RB1, RBL1
6	integral to plasma membrane	GO:005887	15.9	PIGR, LRMP, CNR2, KIR3DL1, SELL, KDR
7	extracellular space	GO:005615	14.9	KIT, SELE, SERPINB9, SERPINB2, VEGFA, VEGFC
8	extracellular region	GO:005576	14.5	PIGR, NCAM1, SERPINA9, SERPINB2, VEGFA, VEGFC
9	external side of plasma membrane	GO:009897	14.1	NCAM1, KIT, SELL, VCAM1, KDR, B2M
10	membrane raft	GO:045121	11.3	BTK, SELE, BCL10, LCK, JAK2, CD79A
11	cell surface	GO:009986	10.8	NCAM1, VEGFA, VCAM1, LGALS1, CD14, CD59

Biological processes related to b-cell lymphomas according to GeneDecks:

(show top 50)    (show all 79)

id	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:006955	17.2	RFX1, CNR2, KIR3DL1, SERPINB9, VAV1, RAG1
2	apoptotic process	GO:006915	16.4	PIM3, PIM1, PDCD2, BTK, NBN, BRCA1
3	positive regulation of transcription from RNA polymerase II promoter	GO:045944	15.2	RELA, RB1, RBL1, BRCA1, VEGFA, LMO2
4	signal transduction	GO:007165	15.0	PDE4A, PDE4B, KIT, VEGFC, RARB, BCR
5	positive regulation of transcription, DNA-dependent	GO:045893	14.4	RFXAP, REL, RELA, RB1, BRCA1, BRCA2
6	negative regulation of apoptotic process	GO:043066	14.4	PIM3, PIK3CG, PIM1, RELA, VEGFA, MYC
7	anti-apoptosis	GO:006916	14.2	PIK3CA, RELA, SERPINB9, SERPINB2, BNIP3, BIRC3
8	cytokine-mediated signaling pathway	GO:019221	14.2	NCAM1, RELA, KIT, VCAM1, CIITA, BAD
9	inflammatory response	GO:006954	14.0	PIK3CG, RELA, CNR2, KIT, SELE, BLNK
10	cell proliferation	GO:008283	13.9	PIM1, NBN, LIG4, BCL2L1, BAK1, FSCN1
11	positive regulation of cell proliferation	GO:008284	13.8	KIT, NBN, VEGFA, VEGFC, MYC, BIRC5
12	response to DNA damage stimulus	GO:006974	13.6	BRCA1, MYC, BCL2, BCL3, BCL6, CHEK2
13	response to drug	GO:042493	13.4	PDE4A, NBN, VEGFC, MYC, BCL2, LGALS1
14	G1/S transition of mitotic cell cycle	GO:000082	13.4	RB1, BCL2, CDKN1A, CDKN2C, CDK2, CDKN1B
15	positive regulation of I-kappaB kinase/NF-kappaB cascade	GO:043123	13.0	REL, RELA, BIRC3, BCL10, LGALS1, CHUK
16	innate immune response	GO:045087	13.0	PIK3CG, RELA, BTK, BCL10, BCL2, BCL2L1
17	response to ethanol	GO:045471	12.9	BCL2, BAK1, S100A8, CD27, CDK1, MGMT
18	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	12.8	MYC, BCL2L11, BCL2L13, LCK, BAD, BAX
19	regulation of apoptotic process	GO:042981	12.7	BTG1, BRCA1, LMNA, BIRC5, BCL3, LGALS1
20	positive regulation of NF-kappaB transcription factor activity	GO:051092	12.7	RELA, BTK, BCL10, CHUK, CD40, IL1B
21	negative regulation of transcription, DNA-dependent	GO:045892	12.6	RELA, RB1, BRCA1, MYB, BIRC5, PATZ1
22	positive regulation of apoptotic process	GO:043065	12.6	RARB, BCL2L11, BCL6, ZBTB16, BAD, BAK1
23	interferon-gamma-mediated signaling pathway	GO:060333	12.6	NCAM1, VCAM1, CIITA, B2M, JAK2, CD44
24	virus-host interaction	GO:019048	12.5	RELA, RB1, RBL1, VCAM1, BNIP3, KDR
25	cellular response to mechanical stimulus	GO:071260	12.5	BNIP3, BCL10, BAD, BAK1, CD40, ITGB1
26	activation of pro-apoptotic gene products	GO:008633	12.5	MYC, BCL2, BCL2L11, BAD, BAK1, BAX
27	cell cycle arrest	GO:007050	12.5	RB1, NBN, MYC, MSH2, ATM, CDKN1A
28	induction of apoptosis by intracellular signals	GO:008629	12.4	BNIP3, MYC, BCL2, BCL2L1, BCL2L11, BAD
29	induction of apoptosis	GO:006917	12.4	BNIP3, BIK, BCL10, BCL2L11, BCL2L13, LCK
30	induction of apoptosis by extracellular signals	GO:008624	12.3	BTK, VAV1, BCL2L11, BAD, BAK1, BAX
31	response to gamma radiation	GO:010332	12.3	BRCA2, MYC, LIG4, BCL2, CHEK2, BAK1
32	cell-cell signaling	GO:007267	12.3	CD70, CD86, CD80, ITGB2, GRB2, IL10
33	T cell costimulation	GO:031295	12.2	PIK3CA, VAV1, LCK, MTOR, CD86, CD80
34	negative regulation of transcription from RNA polymerase II promoter	GO:000122	12.2	NCOR1, NCOR2, MYC, MYB, BMI1, RARB
35	negative regulation of cell proliferation	GO:008285	12.1	BTG1, RARB, BCL11B, BCL6, ZBTB16, BAK1
36	chemotaxis	GO:006935	12.1	S100A8, XCR1, IL4, MAPK14, CCL4, CCL7
37	B cell differentiation	GO:030183	12.1	VCAM1, RAG1, BLNK, BCL11A, BCL6, MSH2
38	positive regulation of B cell proliferation	GO:030890	12.1	BCL2, BCL6, CDKN1A, CD40LG, CD40, CD38
39	G1 phase of mitotic cell cycle	GO:000080	12.0	RB1, RBL1, CDKN1A, CDKN2C, CDKN2B, CDKN1B
40	protein phosphorylation	GO:006468	12.0	PIM3, PIM1, BTK, BIRC5, BCR, CHUK
41	positive regulation of T cell proliferation	GO:042102	12.0	VCAM1, ITGAL, IL12A, IL12B, IL15, IL1B
42	response to toxin	GO:009636	12.0	BCL2, BAX, CDKN1A, CDK1, CDH1, MGMT
43	response to hypoxia	GO:001666	11.7	VEGFA, VCAM1, BNIP3, BCL2, XRCC1, ATM
44	B cell receptor signaling pathway	GO:050853	11.5	BTK, BLK, BCL2, CD79A, CD79B, CD38
45	response to organic cyclic compound	GO:014070	11.5	BAK1, MSH2, JUN, JUNB, CDKN1A, CDK1
46	cell surface receptor signaling pathway	GO:007166	11.4	BIRC3, LEPR, BAG1, CD27, CD14, CD59
47	nerve growth factor receptor signaling pathway	GO:048011	11.4	PIK3CA, RELA, VAV1, BCL2L11, CHUK, BAD
48	platelet activation	GO:030168	10.7	PIK3CA, PIK3CG, VEGFA, VEGFC, VAV1, LCK
49	blood coagulation	GO:007596	10.5	PIK3CA, PIK3CG, SELL, SERPINB2, VEGFA, VEGFC
50	leukocyte migration	GO:050900	10.3	PIK3CA, SELL, LCK, CD58, CD84, ITGA4

Molecular functions related to b-cell lymphomas according to GeneDecks:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:005515	30.1	TRAF1, DRD2, PTEN, PTPN11, PTPRO, PTPN2
2	ATP binding	GO:005524	14.7	PRKCB, PRKCA, NME1, NME2, RIPK1, RIPK4
3	sequence-specific DNA binding transcription factor activity	GO:003700	13.8	MLL, FOXP3, FOSL2, CDKN2A, IRF1, IRF4
4	protein kinase binding	GO:019901	13.4	RELA, BCL10, BCL2L1, CHEK2, LCK, BAD
5	cytokine activity	GO:005125	13.4	IL27, VEGFA, IL3, IL4, IL5, IL6
6	identical protein binding	GO:042802	13.0	TNF, TP63, TP53, TRAF2, AIRE, AKT1
7	protein homodimerization activity	GO:042803	12.5	MSH2, CDA, FOXP3, FIGF, IL12B, IL6R
8	tumor necrosis factor receptor binding	GO:005164	11.9	TNFSF13B, TNFSF14, TNFSF9, LTA, STAT1, TNFSF10
9	protein heterodimerization activity	GO:046982	11.6	BIK, BIRC5, BCL2L1, BCL11A, BCL2, BAD
10	transcription factor binding	GO:008134	11.6	HDAC2, TP53, GATA4, EPAS1, HDAC1, EP300
11	growth factor activity	GO:008083	11.5	IL6, IL7, IL9, CTGF, CXCL12, CSF1
12	enzyme binding	GO:019899	11.3	MDM2, TGFB1, STAT1, PRKCA, CSF3, LYN